Toronto, Ontario – May 11, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it presented its latest anti-cancer technology research at the 111th Annual American Urological Association (“AUA”) Meeting and Exposition in San Diego, California.
Dr. Lothar Lilge, Senior Scientist at Princess Margaret Cancer Centre, University Health Network, (“UHN”) in Toronto and lead author presented Theralase’s latest pre-clinical research in the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).
The AUA Annual Meeting is the largest gathering of urologists in the world and provides unparalleled access to ground breaking research, new guidelines and the latest advances in urologic medicine. Founded in 1902, the AUA is a premier urologic association, providing invaluable support to the urologic community with a mission to promote the highest standards of urological clinical care through education, research and the formulation of health care policy, dealing with diseases of the male and female urinary tract and the male reproductive organs.
The poster presentation was delivered by Dr. Lilge on Monday May 9th, 2016 and can be accessed at the following link.
https://upgrade.theralase.com/anticancer-research/
Dr. Lilge stated that, “It was a great honour to present our latest pre-clinical research results from our laboratory at Princess Margaret. These findings have demonstrated why our novel photosensitizer TLD-1433 should be evaluated in a Phase Ib clinical trial of Photo Dynamic Therapy (“PDT”) for NMIBC.”
Dr. Michael Jewett, uro-oncologist at UHN stated that, “Theralase hosted a Medical and Scientific Advisory Board (“MSAB”) meeting on Saturday May 7th, 2016 attended by myself, Dr. Lothar Lilge, Dr. Arkady Mandel, Dr. Girish Kulkarni, Dr. Ashish Kamat, Dr. Michael O’Donnell, and Roger Dumoulin-White. Dr. Lothar Lilge. scientific Principal Investigator (“PI”) and Dr. Girish Kulkarni as clinical PI presented the latest research results and the clinical protocol, respectively, for the pending Phase Ib clinical trial to be conducted at UHN.”
Roger Dumoulin-White, President and CEO, Theralase stated, “The AUA provides an excellent forum to highlight Theralase’s pre-clinical results, which we expect will advance the treatment of NMIBC. The meeting hosts a wide audience of uro-oncologists interested in the treatment of bladder cancer and will garner interest among those who ultimately may wish to join our Phase II multi-site clinical trial of PDT in NMIBC, pending the successful completion of our Phase Ib clinical study. The MSAB meeting is a great opportunity to present the latest scientific research, clinical protocol and investigator’s brochure to our expert MSAB board for final review prior to our clinical study beginning enrollment in late 2Q2016, pending Investigational Testing Authorization (“ITA”) approval by Health Canada.
The Company is currently completing the sterilization and mechanical testing of its TLD-3400 medical laser probes used to activate TLD-1433 in the bladder of patients afflicted with NMIBC. The testing is expected to be completed in 2Q2016 allowing re-submission of an Investigational Testing Authorization (“ITA”) to Health Canada with an expected approval date in 2Q2016. Pending ITA approval, Theralase and UHN will immediately commence enrolling patients in a Phase Ib NMIBC clinical study with primary outcome measures of safety and tolerability, secondary outcomes of pharmacokinetics (where the PDC accumulates in the body and how it exits the body) and an exploratory outcome measure of efficacy.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225